← Back to headlines
Citi Initiates Buy Rating for Ionis, Alnylam, BioMarin
Citi has started coverage on Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and BioMarin Pharmaceutical with a Buy rating, citing positive catalyst and growth outlooks.
19 May, 18:01 — 19 May, 18:01
Sources
Showing 1 of 1 sources
